Adropin as a potential marker of enzyme-positive acute coronary syndrome

Basit Öğe Kaydı
dc.contributor.authorAydin, Suna
dc.contributor.authorEren, Mehmet Nesimi
dc.contributor.authorYilmaz, Musa
dc.contributor.authorKalayci, Mehmet
dc.contributor.authorYardim, Meltem
dc.contributor.authorAlatas, Omer Dogan
dc.contributor.authorKuloglu, Tuncay
dc.date.accessioned2024-04-24T17:28:06Z
dc.date.available2024-04-24T17:28:06Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: Enzyme-positive acute coronary syndrome (EPACS) can cause injury to or death of the heart muscle owing to prolonged ischaemia. Recent research has indicated that in addition to liver and brain cells, cardiomyocytes also produce adropin. We hypothesised that adropin is released into the bloodstream during myocardial injury caused by acute coronary syndrome (ACS), so serum and saliva levels rise as the myocytes die. Therefore, it could be useful to investigate how ACS affects the timing and significance of adropin release in human subjects. Methods: Samples were taken over three days after admission, from 22 EPACS patients and 24 age-and gendermatched controls. The three major salivary glands (submandibular, sublingual and parotid) were immunohistochemically screened for adropin production, and serum and saliva adropin levels were measured by an enzyme-linked immuno-sorbent wassay (ELISA). Salivary gland cells produce and secrete adropin locally. Results: Serum adropin, troponin I, CK and CK-MB concentrations in the EPACS group became gradually higher than those in the control group up to six hours (p < 0.05), and troponin I continued to rise up to 12 hours after EPACS. The same relative increase in adropin level was observed in the saliva. Troponin I, CK and CK-MB levels started to decrease after 12 hours, while saliva and serum adropin levels started to decrease at six hours after EPACS. In samples taken four hours after EPACS, when the serum adropin value averaged 4.43 ng/ml, the receiver operating characteristic curve showed that the serum adropin concentration indicated EPACS with 91.7% sensitivity and 50% specificity, while when the cut-off adropin value in saliva was 4.12 ng/ml, the saliva adropin concentration indicated EPACS with 91.7% sensitivity and 57% specificity. Conclusion: In addition to cardiac troponin and CK-MB assays, measurement of adropin level in saliva and serum samples is a potential marker for diagnosing EPACS.en_US
dc.identifier.doi10.5830/CVJA-2016-055
dc.identifier.endpage47en_US
dc.identifier.issn1995-1892
dc.identifier.issn1680-0745
dc.identifier.issue1en_US
dc.identifier.pmid27196807
dc.identifier.scopus2-s2.0-85015354734
dc.identifier.scopusqualityQ3
dc.identifier.startpage40en_US
dc.identifier.urihttps://doi.org/10.5830/CVJA-2016-055
dc.identifier.urihttps://hdl.handle.net/11468/20325
dc.identifier.volume28en_US
dc.identifier.wosWOS:000397242600010
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherClinics Cardive Publ Pty Ltden_US
dc.relation.ispartofCardiovascular Journal of Africa
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSalivaen_US
dc.subjectSerumen_US
dc.subjectAdropinen_US
dc.subjectAcute Coronary Syndromeen_US
dc.subjectEnzyme-Positive Acute Coronary Syndromeen_US
dc.subjectMyocardial Infarctionen_US
dc.subjectImmunohistochemistryen_US
dc.titleAdropin as a potential marker of enzyme-positive acute coronary syndromeen_US
dc.titleAdropin as a potential marker of enzyme-positive acute coronary syndrome
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu